<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03705949</url>
  </required_header>
  <id_info>
    <org_study_id>226/15-03-2018</org_study_id>
    <nct_id>NCT03705949</nct_id>
  </id_info>
  <brief_title>Impact of 0.1% and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Phacoemulsification Surgery</brief_title>
  <official_title>Impact of 0.1% Sodium Hyaluronate and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Cataract Extraction Surgery, a Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Democritus University of Thrace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naval Hospital, Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Papanicolaou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Athinaiki General Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Democritus University of Thrace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is the assessment of the patients' discomfort following
      cataract extraction surgery by means of phacoemulsification and intraocular lens
      implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be recruited from the Cataract Service of the University Hospital of
      Alexandroupolis (UHA), the Naval Hospital in Athens, the Papanikolaou General Hospital in
      Thessaloniki, and Athinaiki General Clinic in Athens in a consecutive-if-eligible basis. By
      means of a custom computer randomization program all participants will randomly populate
      either study group [who will receive fixed combination of tobramycin and dexamethasone
      (FCTD), (Tobradex, Alcon, Greece) quid for 3 weeks and 0.2 % sodium hyaluronate (Hylogel,
      Pharmex, Greece) quid for 6 weeks], and control group [who will receive Tobradex quid for 3
      weeks and 0.1 % sodium hyaluronate (Hylocomod) quid for 6 weeks].
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">September 15, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surface Discomfort Index</measure>
    <time_frame>6 weeks</time_frame>
    <description>A subjective parameter that quantifies corneal discomfort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Break up time</measure>
    <time_frame>6 weeks</time_frame>
    <description>An objective parameter that quantifies stability of tear film</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Corneal Sensitivity</measure>
    <time_frame>6 weeks</time_frame>
    <description>An objective parameter that quantifies corneal sensitivity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Hyaluronate 0.1% drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Hyaluronate 0.2% drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate 0.1% drops</intervention_name>
    <description>Patients will be administered Drops of Sodium Hyaluronate 0.1% quid</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Sodium Hyaluronate 0.1% drops (artificial tear medication)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate 0.2% drops</intervention_name>
    <description>Patients will be administered Drops of Sodium Hyaluronate 0.2% quid</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Sodium Hyaluronate 0.2% drops (artificial tear medication)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of senile cataract with stage 2 or 3 nuclear opalescence according to the -
             Lens Opacities Classification System III (LOCS-3) grading scale

        Exclusion Criteria:

          1. Diagnosis or evidence of dry-eye-disease (DED)

          2. IOP-lowering medications

          3. Former incisional surgery

          4. Former diagnosis of corneal disease

          5. Diabetes

          6. Autoimmune diseases

          7. Mental diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios Labiris, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Alexandroupolis, Democritus University of Thrace</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Alexandroupolis</name>
      <address>
        <city>Alexandroupolis</city>
        <state>Evros</state>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>October 11, 2018</last_update_submitted>
  <last_update_submitted_qc>October 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Democritus University of Thrace</investigator_affiliation>
    <investigator_full_name>Georgios Labiris</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

